Abstract: Methods for high level expression of active lymphotoxin-? receptor immunoglobulin chimeric proteins and their purification.

Abstract: The compositions and methods of the present invention are based, in part, on our discovery that an effector function mediated by an Fc-containing polypeptide can be altered by modifying one or more amino acid residues within the polypeptide (by, for example, electrostatic optimization). The polypeptides that can be generated according to the methods of the invention are highly variable, and they can include antibodies and fusion proteins that contain an Fc region or a biologically active portion thereof.

Abstract: The invention provides methods and compositions for separating impurities during the manufacture of immunoglobulin (Ig) fusion proteins. Examples of impurities which may be removed in accordance with the methods of the invention include inactive forms of the Ig fusion protein and/or aggregates.

Abstract: Methods for high level expression of active lymphotoxin-? receptor immunoglobulin chimeric proteins and their purification.

Abstract: Methods of treating disease with soluble inhibitors of the lymphotoxin pathway having improved properties. Improved LTBR-Ig fusion proteins, and pharmaceutical compositions thereof, are also described.

Abstract: The invention relates to a method for controlling an induction cooking appliance with at least one coil, wherein the power of the coil is adjusted as a function of a position of a cooking utensil on the coil. The invention also relates to an induction cooking appliance for heating a cooking utensil, which has at least one coil and a drive unit for the coil, the induction cooking appliance being designed to implement the mentioned method.

Abstract: The geometric dimensions and shape of a device for removing solid particles from the cooling medium that is circulated in the primary circuit of a nuclear reactor, in particular a boiling water nuclear reactor, are such that the device can be inserted in lieu of a fuel element or fuel assembly into an empty fuel element or assembly position of the reactor core of the nuclear reactor.

Abstract: Methods for high level expression of active lymphotoxin-? receptor immunoglobulin chimeric proteins and their purification.

Abstract: This invention relates to compositions and methods useful for activating LT-? receptor signaling, which in turn elicits potent anti-proliferative effects on tumor cells. More particularly, this invention relates to lymphotoxin heteromeric complexes formed between lymphotoxin-a and multiple subunits of lymphotoxin-?, which induce cytotoxic effects on tumor cells in the presence of lymphotoxin-? receptor activating agents. Also within the scope of this invention are antibodies directed against the lymphotoxin-? receptor which act as lymphotoxin-? receptor activating agents alone or in combination with other lymphotoxin-? receptor activating agents either in the presence or absence of lymphotoxin-a/? complexes. A screening method for selecting such antibodies is provided. This invention also relates to compositions and methods using cross-linked anti-lymphotoxin-? receptor antibodies either alone or in the presence of other lymphotoxin-? receptor activating agents to potentiate tumor cell cytotoxicity.

Abstract: Disclosed are immunogenic Nogo receptor-1 polypeptides, Nogo receptor-1 antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof and nucleic acids encoding the same. Also disclosed are Nogo receptor antagonist polynucleotides. Also disclosed are compositions comprising, and methods for making and using, such Nogo receptor antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof, nucleic acids encoding the same and antagonist polynucleotides.

Abstract: This invention relates to compositions and methods useful for activating LT-? receptor signaling, which in turn elicits potent anti-proliferative effects on tumor cells. More particularly, this invention relates to lymphotoxin heteromeric complexes formed between lymphotoxin-? and multiple subunits of lymphotoxin-?, which induce cytotoxic effects on tumor cells in the presence of lymphotoxin-? receptor activating agents. Also within the scope of this invention are antibodies directed against the lymphotoxin-? receptor which act as lymphotoxin-? receptor activating agents alone or in combination with other lymphotoxin-? receptor activating agents either in the presence or absence of lymphotoxin-?/? complexes. A screening method for selecting such antibodies is provided. This invention also relates to compositions and methods using cross-linked anti-lymphotoxin-? receptor antibodies either alone or in the presence of other lymphotoxin-? receptor activating agents to potentiate tumor cell cytotoxicity.

Abstract: The compositions and methods of the present invention are based, in part, on our discovery that an effector function mediated by an Fc-containing polypeptide can be altered by modifying one or more amino acid residues within the polypeptide (by, for example, electrostatic optimization). The polypeptides that can be generated according to the methods of the invention are highly variable, and they can include antibodies and fusion proteins that contain an Fc region or a biologically active portion thereof.

Abstract: This invention relates to compositions and methods useful for treating or reducing the advancement, severity or effects of neoplasia by the administration of at least two or more lymphotoxin beta receptor (LT-? receptor) activating agents where at least one LT-? receptor activating agent is an anti-LT-? receptor antibody.

Abstract: This invention relates to compositions and methods useful for activating LT-? receptor signaling, which in turn elicits potent anti-proliferative effects on tumor cells. More particularly, this invention relates to lymphotoxin heteromeric complexes formed between lymphotoxin-? and multiple subunits of lymphotoxin-?, which induce cytotoxic effects on tumor cells in the presence of lymphotoxin-? receptor activating agents. Also within the scope of this invention are antibodies directed against the lymphotoxin-? receptor which act as lymphotoxin-? receptor activating agents alone or in combination with other lymphotoxin-? receptor activating agents either in the presence or absence of lymphotoxin-?/? complexes. A screening method for selecting such antibodies is provided. This invention also relates to compositions and methods using cross-linked anti-lymphotoxin-? receptor antibodies either alone or in the presence of other lymphotoxin-? receptor activating agents to potentiate tumor cell cytotoxicity.

Abstract: A fuel assembly for a boiling water reactor has a plurality of fuel rods which are mounted in a plurality of spacers disposed at a spacing distance from each other in the axial direction of the fuel element. At least one of the fuel rods has a reduced length. Deflection elements are arranged at least in the upper region of the fuel element in order to improve the dry-out behavior of the assembly. The fuel assembly further includes measures that reduce a loss of pressure caused in the upper region by the deflecting elements so as to improve thermo-hydraulic stability and the shutdown behavior.

Abstract: A fuel element for a nuclear reactor has fuel rods with nuclear fuel guided through spacers. The spacers are equipped with devices that exert a swirling impulse upon a coolant flowing along the fuel rods. In order to present as little flow resistance as possible for the coolant, these swirl-introducing devices have the form of a vane with a spoonlike or bladelike shape and they extend into the coolant flow. Owing to the shape—here the vane is curved in the longitudinal and in the transverse directions—practically all cross sections of the vane have such a high geometrical moment of inertia that even a vane made of a thin sheet metal is sufficiently rigid. Fuel elements configured according to the invention are particularly suitable for use in boiling water nuclear reactors.

Abstract: A fuel element for a nuclear reactor has fuel rods with nuclear fuel guided through spacers. The spacers are equipped with devices that exert a swirling impulse upon a coolant flowing along the fuel rods. In order to present as little flow resistance as possible for the coolant, these swirl-introducing devices have the form of a vane with a spoonlike or bladelike shape and they extend into the coolant flow. Owing to the shape—here the vane is curved in the longitudinal and in the transverse directions—practically all cross sections of the vane have such a high geometrical moment of inertia that even a vane made of a thin sheet metal is sufficiently rigid. Fuel elements configured according to the invention are particularly suitable for use in boiling water nuclear reactors.

Abstract: This invention relates to compositions and methods useful for treating or reducing the advancement, severity or effects of neoplasia by the administration of at least two or more lymphotoxin beta receptor (LT-&bgr; receptor) activating agents where at least one LT-&bgr; receptor activating agent is an anti-LT-&bgr; receptor antibody.

Abstract: Methods for high level expression of active lymphotoxin-&bgr; receptor immunoglobulin chimeric proteins and their purification.

Abstract: This invention relates to compositions and methods useful for activating LT-&bgr; receptor signaling, which in turn elicits potent anti-proliferative effects on tumor cells. More particularly, this invention relates to lymphotoxin heteromeric complexes formed between lymphotoxin-&agr; and multiple subunits of lymphotoxin-&bgr;, which induce cytotoxic effects on tumor cells in the presence of lymphotoxin-&bgr; receptor activating agents. Also within the scope of this invention are antibodies directed against the lymphotoxin-&bgr; receptor which act as lymphotoxin-&bgr; receptor activating agents alone or in combination with other lymphotoxin-&bgr; receptor activating agents either in the presence or absence of lymphotoxin-&agr;/&bgr; complexes. A screening method for selecting such antibodies is provided.